Article

Current Prostate Cancer Treatments May Promote Relapse

Medical androgen deprivation therapies combined with other treatments may cause relapse in patients with prostate cancer.

In a study published by Science Translational Medicine, researchers found that androgen deprivation therapies (ADTs) may suppress adaptive immune responses.

This suppression prevents immunotherapies from working properly, the study noted.

"Medical ADTs have been used for a half century to treat prostate cancer, and promising clinical results for cancer immunotherapy have led to attempts to combine it and other standard-of-care therapies with immunotherapy to treat the disease," said senior author Yang-Xin Fu, MD, PhD, in a press release.

Researchers found that some ADTs can reduce T cell response against prostate cancer, which can lead to tumor relapse. Suppressed immune systems block the efficacy of any immunotherapy and can lead to relapse.

Some patients could have a poor immune response due to the radiation or chemotherapy suppressing the immune response, the study noted.

Researchers said that although these treatments may suppress the immune response, resistant clones will survive and the tumor can relapse more aggressively.

Regulating timing, types, and dosage of ADTs used with immunotherapy can greatly maximize the treatment, the study concluded.

"We hope that our findings will cause physicians to think twice before starting chemotherapy or radiation on their cancer patients, to consider the best way to combine them with immunotherapies," Dr Fu said. "The idea is to kill the tumor cells while also considering whether these therapies are suppressing or activating the immune system."

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com